Physical Optics Corporation — Department of Defense SBIR Phase I: CBD152-003

Description

To address the Chemical and Biological Defense programs (CBDs) need for medical countermeasures against mycotoxin intoxication, PhysicalOptics Corporation (POC) proposes to develop a new Mycotoxin Neutralization Treatment (MyNT). This proposed solution is based on neutralizingmycotoxin from its deleterious effects by acting on multiple levels of mycotoxin metabolism through the novel combination of active compounds inMyNT. MyNT has the potential to neutralize mycotoxins at low doses and increase survival from an acute mycotoxin exposure, whether alone orconcurrent with other toxins and pathogens, which directly address CBDs need for medical countermeasure against the use of mycotoxins aschemical warfare agents. In Phase I, POC will perform proof-of-concept experiments to demonstrate the feasibility of MyNT to neutralizemycotoxins in a lethal in vitro model. In Phase II, POC plans to evaluate MyNT in a small mammal study for efficacy against mycotoxin exposurealong and concurrently with another toxin such as Staphylococcal enterotoxin A or B. Non-clinical GLP pharmacokinetic (PK) andpharmacodynamic (PD) data will also be collected to facilitate transition to Phase III and clinical testing.